GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 11th Nov 2013 08:50

Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p.Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation.British Land: Deutsche Bank downgrades to sell with a target price of 520p.British Sky Broadcasting: Nomura reduces target price from 1040p to 850p and downgrades from buy to reduce. Goldman Sachs cuts target price from 1120p to 1070p, while reiterating its buy recommendation.BT Group: JP Morgan increases target price from 380p to 420p upgrading from neutral to overweight. Citi ups target price from 400p to 430p retaining a buy recommendation. UBS cuts target price from 310p to 290p and stays with its sell recommendation.Cable & Wireless Communications: Jefferies shifts target price from 45p to 48p and retains a hold recommendation.Carr's Milling: Investec places both its target price (prev.: 1710p) and its buy recommendation under review.Cobham: Investec cuts target price from 275p to 230p retaining its sell recommendation.Dignity: Investec raises target price from 1562p to 1583p and upgrades from add to buy.Faroe Petroleum: Panmure Gordon moves target price from 182p to 188p and retains a buy recommendation. Westhouse Securities shifts target price from 175p to 185p and maintains a buy recommendation.FlyBe: Liberum Capital initiates with a target price of 90p and a buy recommendation.Gemfields: Investec moves target price from 30p to 37.5p and reiterates a buy recommendation.International Consolidated Airlines Group: Citi raises target price from 380p to 535p and stays with its buy recommendation. HSBC takes target price from 405p to 420p maintaining an overweight rating. Credit Suisse increases target price from 345p to 443p and reiterates an outperform rating.International Personal Finance: RBC Capital shifts target price from 700p to 695p and maintains an outperform rating.ITV: Citi ups target price from 180p to 191p, while downgrading from buy to neutral. Goldman Sachs lowers target price from 240p to 237p and retains a buy recommendation.Lonmin: Investec places its target price (prev.: 266p), while leaving its sell recommendation unaltered.Morgan Advanced Materials: Investec places its target price (prev.: 410p) under review, while keeping its buy recommendation.Paragon Group: RBC Capital ups target price from 350p to 390p upgrading to outperform.Rentokil Initial: JP Morgan moves target price from 75p to 86p, while leaving its underweight rating unchanged.Royal Bank of Scotland: Jefferies raises target price from 390p to 441p and keeps a buy recommendation.RSA Insurance Group: Citi reduces target price from 146p to 126p downgrading from buy to neutral. Panmure Gordon moves target price from 98p to 117p, but still recommends selling. Credit Suisse lowers target price from 125p to 110p and downgrades to underperform.Shire: Panmure Gordon raises target price from 2850p to 3100p and keeps a buy recommendation.Tullett Prebon: UBS cuts target price from 315p to 290p and maintains its sell recommendation.Verona Pharma: N+1 Singer initiates with a target price of 5.1p and a buy recommendation.Wincanton: Investec ups target price from 75p to 122p, while downgrading from buy to hold.
More News
2 Mar 2018 15:01

BUZZ-Verona Pharma: Soars on positive data from mid-stage study

** British drug developer's U.S.-listed shares up 16 pct at $16.44 in morning trade - second highest gainer amongst Nasdaq-listed companies ** data a

Read more
18 Jan 2017 10:13

Verona Pharma Proposes Share Consolidation Amid Plans To List In US (ALLISS)

Read more
26 Sep 2016 09:39

Verona Pharma appoints sector veteran Morgan as CFO

(ShareCast News) - AIM listed drug development company Verona Pharma appointed sector veteran Piers John Morgan as chief financial officer on Monday, as the company prepares for clinical trials for its flagship drug. Chartered accountant Morgan has 25 years' financial experience and was previously c

Read more
13 Sep 2016 12:04

Verona Pharma makes progress on new respiratory drug

(ShareCast News) - Verona Pharma, a UK based drug development company focused on first-in-class medicines to treat respiratory diseases, reported positive results on new drug "RPL554". The company's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulized maintenance tr

Read more
20 Jun 2016 15:02

UK Shareholder Meetings Calendar - Next 7 Days

Read more
20 Jun 2016 12:50

Verona Pharma secures funding for drug trial

(ShareCast News) - Shares in AIM-listed Verona Pharma rallied on Monday as the drug development company it had successfully secured funding commitments to raise gross proceeds of around £44.7m through a conditional placing that was significantly oversubscribed. Net proceeds from the placing with new

Read more
20 Jun 2016 11:06

LONDON MARKET MIDDAY: Receding Brexit Fear Lifts Stocks And Pound

Read more
20 Jun 2016 09:40

WINNERS & LOSERS SUMMARY: Cat Allergy Disappointment Sinks Circassia

Read more
17 Jun 2016 16:09

Verona Pharma To Raise GBP44.7 Million In Share Placing (ALLIS)

Read more
3 Jun 2016 12:52

Verona Pharma's shares fall as higher R&D costs widen FY loss

(ShareCast News) - Shares in Verona Pharma sagged more than 8% as it turned in a wider full-year pre-tax loss of £8.9m, from a loss of £3.8m, thanks to higher research and development more than doubling. Chief executive Jan-Anders Karlsson said Verona had made substantial clinical progress with its

Read more
3 Jun 2016 06:59

Verona Pharma Loss Widens On Higher Research And Development Costs

Read more
10 May 2016 08:11

Verona Pharma Gets Positive Results From COPD Treatment Study

Read more
15 Mar 2016 10:35

Verona Pharma excites with asthma trial results

(ShareCast News) - Verona Pharma has published further encouraging clinical results for its RPL554 drug to treat chronic obstructive pulmonary disorder (COPD). Tests among asthma patients found the inhaled drug, which has both bronchodilator and anti-inflammatory properties in the same active molecu

Read more
21 Jan 2016 13:31

DIRECTOR DEALINGS: Verona Pharma Chairman Ups Interest

Read more
11 Jan 2016 08:45

Verona Pharma Chief Financial Officer Biresh Roy Leaving Company

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.